APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-secretase modulation

Stem Cell Reports

Volumn 1, Issue 6, 2013, Pages 491-498

  Mertens, Jerome ^a,f   Stüber, Kathrin ^a,b   Wunderlich, Patrick ^a   Ladewig, Julia ^a   Kesavan, Jaideep C ^a   Vandenberghe, Rik ^c,d   Vandenbulcke, Mathieu ^c   Van Damme, Philip ^c,d,e   Walter, Jochen ^a   Brüstle, Oliver ^a,b   Koch, Philipp ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Life and Brain Center   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; DICLOFENAC; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GENOMIC DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; IBUPROFEN; IMATINIB; INDOMETACIN; N [N (3,5 DIFLUOROPHENACETYL) 1 ALANYL] S PHENYLGLYCINE TERT BUTYL ESTER; NAPROXEN; NESTIN; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHANNEL; PRESENILIN 1; PROTEIN ZO1; SODIUM CHANNEL; TAU PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CULTURE MEDIUM; DONOR; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KARYOTYPE; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL MEMBRANE STEADY POTENTIAL; NEURAL STEM CELL; NEUROECTODERM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; TERATOMA; TRANSGENE; WHOLE CELL PATCH CLAMP; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DRUG EFFECTS; EMBRYONIC STEM CELL; ENZYMOLOGY; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DIFFERENTIATION; CELL LINE; EMBRYONIC STEM CELLS; HUMANS; NEURONS; PEPTIDE FRAGMENTS; PLURIPOTENT STEM CELLS;

EID: 84891025045     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2013.10.011     Document Type: Article

References (34)

1. B. Bannwarth, P. Netter, F. Lapicque, P. Péré, P. Thomas, and A. Gaucher Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity Eur. J. Clin. Pharmacol. 38 1990 343 346
2. K. Blennow, H. Zetterberg, and A.M. Fagan Fluid biomarkers in Alzheimer disease Cold Spring Harb Perspect Med 2 2012
3. D.R. Borchelt, G. Thinakaran, C.B. Eckman, M.K. Lee, F. Davenport, T. Ratovitsky, C.M. Prada, G. Kim, S. Seekins, and D. Yager et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo Neuron 17 1996 1005 1013
4. M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A.Y. Hung, P. Seubert, C. Vigo-Pelfrey, I. Lieberburg, and D.J. Selkoe Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production Nature 360 1992 672 674
5. D. de Jong, R. Jansen, W. Hoefnagels, M. Jellesma-Eggenkamp, M. Verbeek, G. Borm, and B. Kremer No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial PLoS ONE 3 2008 e1475
6. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J. Clin. Invest. 112 2003 440 449
7. A. Falk, P. Koch, J. Kesavan, Y. Takashima, J. Ladewig, M. Alexander, O. Wiskow, J. Tailor, M. Trotter, and S. Pollard et al. Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons PLoS ONE 7 2012 e29597
8. D.R. Galasko, N. Graff-Radford, S. May, S. Hendrix, B.A. Cottrell, S.A. Sagi, G. Mather, M. Laughlin, K.H. Zavitz, and E. Swabb et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis. Assoc. Disord. 21 2007 292 299
9. A.K. Ghosh, M. Brindisi, and J. Tang Developing β-secretase inhibitors for treatment of Alzheimer's disease J. Neurochem. 120 Suppl 1 2012 71 83
10. T.E. Golde, L.S. Schneider, and E.H. Koo Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift Neuron 69 2011 203 213
11. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, E.A. Swabb, K.H. Zavitz Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
12. C. Haass, C. Kaether, G. Thinakaran, and S. Sisodia Trafficking and proteolytic processing of APP Cold Spring Harb. Perspect. Med. 2 2012 a006270
13. B.P. Imbimbo, and G.A. Giardina γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes Curr. Top. Med. Chem. 11 2011 1555 1570
14. M.A. Israel, S.H. Yuan, C. Bardy, S.M. Reyna, Y. Mu, C. Herrera, M.P. Hefferan, S. Van Gorp, K.L. Nazor, and F.S. Boscolo et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells Nature 482 2012 216 220
15. T. Jumpertz, A. Rennhack, J. Ness, S. Baches, C.U. Pietrzik, B. Bulic, and S. Weggen Presenilin is the molecular target of acidic γ-secretase modulators in living cells PLoS ONE 7 2012 e30484
16. E. Karran, M. Mercken, and B. De Strooper The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discov. 10 2011 698 712
17. P. Koch, T. Opitz, J.A. Steinbeck, J. Ladewig, and O. Brüstle A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration Proc. Natl. Acad. Sci. USA 106 2009 3225 3230
18. P. Koch, P. Breuer, M. Peitz, J. Jungverdorben, J. Kesavan, D. Poppe, J. Doerr, J. Ladewig, J. Mertens, and T. Tüting et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease Nature 480 2011 543 546
19. P. Koch, I.Y. Tamboli, J. Mertens, P. Wunderlich, J. Ladewig, K. Stüber, H. Esselmann, J. Wiltfang, O. Brüstle, and J. Walter Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation Am. J. Pathol. 180 2012 2404 2416
20. T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, G.M. Maharvi, B. Healy, R. Chapman, A.T. Welzel, and R.W. Price et al. Substrate-targeting γ-secretase modulators Nature 453 2008 925 929
21. S. Kumar-Singh, J. Theuns, B. Van Broeck, D. Pirici, K. Vennekens, E. Corsmit, M. Cruts, B. Dermaut, R. Wang, and C. Van Broeckhoven Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40 Hum. Mutat. 27 2006 686 695
22. E. Kumpulainen, P. Välitalo, M. Kokki, M. Lehtonen, A. Hooker, V.P. Ranta, and H. Kokki Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children Br. J. Clin. Pharmacol. 70 2010 557 566
23. A.J. Larner, and M. Doran Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene J. Neurol. 253 2006 139 158
24. V.B. Mattis, and C.N. Svendsen Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol. 10 2011 383 394
25. J. Mertens, K. Stüber, D. Poppe, J. Doerr, J. Ladewig, O. Brüstle, and P. Koch Embryonic stem cell-based modeling of tau pathology in human neurons Am. J. Pathol. 182 2013 1769 1779
26. L. Rajendran, H.J. Knölker, and K. Simons Subcellular targeting strategies for drug design and delivery Nat. Rev. Drug Discov. 9 2010 29 42
27. W.A. Ritschel Handbook of Basic Pharmacokinetics - Including Clinical Applications 1999 American Pharmaceutical Association Washington, DC
28. D.J. Selkoe Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81 2001 741 766
29. D. Selkoe, E. Mandelkow, and D. Holtzman Deciphering Alzheimer disease Cold Spring Harb. Perspect. Med. 2 2012 a011460
30. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka Induction of pluripotent stem cells from adult human fibroblasts by defined factors Cell 131 2007 861 872
31. J. Theuns, E. Marjaux, M. Vandenbulcke, K. Van Laere, S. Kumar-Singh, G. Bormans, N. Brouwers, M. Van den Broeck, K. Vennekens, and E. Corsmit et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment Hum. Mutat. 27 2006 888 896
32. B. Vellas Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed Lancet Neurol. 9 2010 235 237
33. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, and T. Bulter et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 2001 212 216
34. J. Wiltfang, H. Esselmann, P. Cupers, M. Neumann, H. Kretzschmar, M. Beyermann, D. Schleuder, H. Jahn, E. Rüther, and J. Kornhuber et al. Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells J. Biol. Chem. 276 2001 42645 42657